81 completed, 45 unknown, 38 recruiting, 28 terminated. 82 Phase 2, 66 Phase 1, 35 Phase 3, 25 Not applicable, 3 Early Phase 1.
Follow Epithelial Ovarian Cancer: new trials by email Literature Review of Epithelial Ovarian Cancer trials Research Report on Epithelial Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 950 | 2026-09-16 | 2026-10-01 |
| Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in Italy HRD test - Epithelial Ovarian Cancer | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1125 | 2026-09-01 | 2026-09-17 | |
| 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer 89Zr-DFO-Mirvetuximab PET/CT - Epithelial Ovarian Cancer, Ovarian Cancer | Early Phase 1 | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2026-09-01 | 2026-08-27 |
| IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Sacituzumab govitecan monotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 19 | 2026-07-01 | 2026-06-30 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [68Ga]BED003 - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-06-30 | 2026-09-15 |
| Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer Surgery Sentinel Lymph Node Mapping, Indocyanine Green - Epithelial Ovarian Cancer | Not applicable | Not yet recruiting | Başakşehir Çam & Sakura City Hospital | 30 | 2026-06-01 | 2026-05-18 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-05-18 |
| Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer Epithelial Ovarian Cancer | Recruiting | University of Tennessee Graduate School of Medicine | 50 | 2026-05-13 | 2026-08-17 | |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-01 |
| Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer EB-DUALNK, Cyclophosphamide, Fludarabine - Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-05-15 |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [18F]FPyQCP - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-02-19 | 2026-06-23 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-02-04 | 2026-03-18 |
| A Study of Isoquercetin in People With Ovarian Cancer Isoquercetin, Placebo - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 90 | 2026-01-22 | 2026-09-15 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-29 | 2026-07-21 |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Carboplatin, Mirvetuximab Soravtansine, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | AbbVie | 140 | 2025-11-21 | 2026-10-20 |
| Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) Daphne Extract Capsules - Epithelial Ovarian Cancer | Not applicable | Recruiting | The First Hospital of Jilin University | 98 | 2025-11-01 | 2026-03-27 |
| Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT Prehabilitation - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Case Comprehensive Cancer Center | 1 | 2025-09-05 | 2026-09-15 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 450 | 2025-08-04 | 2026-07-07 |
Showing 20 of 225. Sign in to see all of them.
Carcinoma, Ovarian Epithelial (225) · Fallopian Tube Neoplasms (85) · Ovarian Neoplasms (67) · Colorectal Neoplasms (13) · Recurrence (12) · Carcinoma, Non-Small-Cell Lung (11) · Neoplasms (10) · Triple Negative Breast Neoplasms (10) · Stomach Neoplasms (9) · Carcinoma, Renal Cell (8) · Endometrial Neoplasms (8) · Melanoma (8) · Small Cell Lung Carcinoma (8) · Squamous Cell Carcinoma of Head and Neck (7) · Uterine Cervical Neoplasms (7)
Adnexal Diseases (225) · Endocrine Gland Neoplasms (225) · Endocrine System Diseases (225) · Female Urogenital Diseases (225) · Female Urogenital Diseases and Pregnancy Complications (225) · Genital Diseases (225) · Genital Diseases, Female (225) · Gonadal Disorders (225) · Neoplasms by Histologic Type (225) · Neoplasms by Site (225) · Neoplasms, Glandular and Epithelial (225) · Urogenital Diseases (225) · Urogenital Neoplasms (225) · Ovarian Diseases (224) · Carcinoma (223)
Paclitaxel (29) · Carboplatin (27) · Bevacizumab (15) · liposomal doxorubicin (15) · pembrolizumab (11) · Hyperthermic Intraperitoneal Chemotherapy (10) · Topotecan (9) · Cisplatin (8) · mirvetuximab soravtansine (8) · Cyclophosphamide (7) · Gemcitabine (7) · Nivolumab (6) · niraparib (6) · rucaparib (6) · 1-dodecylpyridoxal (5)
Lei Li (13) · Shanghai Gynecologic Oncology Group (6) · Memorial Sloan Kettering Cancer Center (5) · pharmaand GmbH (5) · AstraZeneca (4) · University Health Network, Toronto (4) · ARCAGY/ GINECO GROUP (3) · Beijing Biotech (3) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (3) · ImmunoGen, Inc. (3) · Imunon (3) · Morphotek (3) · Prima BioMed Ltd (3) · RenJi Hospital (3) · AbbVie (2)
United States (93) · China (46) · Canada (26) · Spain (21) · Australia (20) · Italy (19) · France (17) · South Korea (17) · Germany (16) · Belgium (15) · United Kingdom (14) · Israel (9) · Netherlands (9) · Japan (8) · Sweden (8)
Lei Li, M.D. (10) · Amit Oza, M.D. (2) · Dennis Chi, MD (2) · Fernando Recio, MD (2) · Giuseppe Del Priore, MD (2) · James Mason, MD (2) · Linda Van Le, MD (2) · Nicole Urban, ScD (2) · Peter Eisenberg, MD (2) · Shuzhong Cui, M.D (2) · Susan Weil, MD (2) · Ursula Matulonis, MD (2) · Zhongqiu Lin, M.D (2)
PMID 37407274, PMID 35262624, PMID 36608308, PMID 16260202, PMID 17000396, PMID 19169758, PMID 19767092, PMID 19819917, PMID 21056906, PMID 21945640, PMID 22014006, PMID 22542580, PMID 22564713, PMID 22960352, PMID 23032745, PMID 23142076, PMID 23948349, PMID 23994535, PMID 24356636, PMID 24777970, PMID 24849521, PMID 25304260, PMID 25827292, PMID 25877891, PMID 26707054, PMID 26782955, PMID 26998845, PMID 27330807, PMID 27908594, PMID 27998224, PMID 27998236, PMID 28453702, PMID 28528917, PMID 29342393, PMID 30213835, PMID 30431292, PMID 31046081, PMID 31142357, PMID 31171691, PMID 31467066, PMID 31685558, PMID 31791552, PMID 31826802, PMID 32689832, PMID 32808504, PMID 32994466, PMID 33030975, PMID 33433743, PMID 33554038, PMID 33667670
2008 (1), 2009 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1), 2025 (1), R01CA256898 (1)